Endoluminal radiofrequency ablation of malignant biliary
stenoses

a 2015

Endoluminal radiofrequency ablation of malignant biliary stenoses

ANDRAŠINA, Tomáš, Jiří PÁNEK, Jan HLAVSA, Vladan BERNARD, Vlastimil VÁLEK et. al.

Základní údaje

Originální název

Endoluminal radiofrequency ablation of malignant biliary stenoses

Autoři

ANDRAŠINA, Tomáš (703 Slovensko, garant, domácí), Jiří PÁNEK (203 Česká republika, domácí), Jan HLAVSA (203 Česká republika, domácí), Vladan BERNARD (203 Česká republika, domácí) a Vlastimil VÁLEK (203 Česká republika, domácí)

Vydání

European Congress of Radiology 2015, 2015

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

30000 3. Medical and Health Sciences

Stát vydavatele

Rakousko

Utajení

není předmětem státního či obchodního tajemství

Kód RIV

RIV/00216224:14110/15:00087460

Organizační jednotka

Lékařská fakulta

ISSN

DOI

http://dx.doi.org/10.1007/s13244-015-0387-z

Klíčová slova anglicky

endoluminal ablation biliary

Štítky

EL OK

Změněno: 6. 4. 2016 12:33, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

Purpose: To prove efficacy of endoluminal radiofrequency ablation before stenting of malignant biliary stenoses. Methods and Materials: 54 patients with histologically proven malignant biliary stenoses have been enrolled in a prospective randomised study from 2010. 73 non-covered self-expandable metal stents were inserted. In group A (n=22) the endoluminal ablation with a bipolar radiofrequency catheter (EndoHPB;EMcision Ltd.,London,UK) was performed 0-48hours prior to the stent insertion, in group B (n=32) the stent was implanted without a prior ablation. The primary endpoints of the study were to determine the rate of complications, duration of stent patency and survival of patients (Kaplan-Meyer analysis). Results: No major complications related to the stent insertion and endoluminal ablation were recorded. 30 day mortality was 3.7%. The average primary stent patency was 5.6 and 5.2 months in group A and B, respectively, 3-months and 6-months stent failure was 9.1% and 13.6% in group A and 15% and 25% in group B. The median survival from the insertion of the stent was 5.9 (2.9-6.7) and 5.4 (3.7-8.6) months, the median survival from the initial drainage was 9.6 (5.6-12.2) and 8.5 (5.8-12.7) months in group A and B, respectively. The difference was not statistically significant. Conclusion: In the prospective randomised clinical study the effect of an endoluminal ablation on patients survival was not proven. However, in the group of patients undergoing ablation there is a tendency of a lower rate of early stent failure. In addition, the intervention was not associated with higher rates of complications.

Návaznosti

NT14586, projekt VaV

Název: Choledochoskopem navigovaná radiofrekvenční ablace žlučových cest.

Investor: Ministerstvo zdravotnictví ČR, Choledochoskopem navigovaná radiofrekvenční ablace žlučových cest.

Citovat

ANDRAŠINA, Tomáš, Jiří PÁNEK, Jan HLAVSA, Vladan BERNARD a Vlastimil VÁLEK. Endoluminal radiofrequency ablation of malignant biliary stenoses. In European Congress of Radiology 2015. 2015. ISSN 1869-4101. Dostupné z: https://dx.doi.org/10.1007/s13244-015-0387-z.

@proceedings{1317130,
   author = {Andrašina, Tomáš and Pánek, Jiří and Hlavsa, Jan and Bernard, Vladan and Válek, Vlastimil},
   booktitle = {European Congress of Radiology 2015},
   doi = {http://dx.doi.org/10.1007/s13244-015-0387-z},
   keywords = {endoluminal ablation biliary},
   language = {eng},
   title = {Endoluminal radiofrequency ablation of malignant biliary stenoses},
   year = {2015}
}

TY  - CONF
ID  - 1317130
AU  - Andrašina, Tomáš - Pánek, Jiří - Hlavsa, Jan - Bernard, Vladan - Válek, Vlastimil
PY  - 2015
TI  - Endoluminal radiofrequency ablation of malignant biliary stenoses
KW  - endoluminal ablation biliary
N2  - Purpose: To prove efficacy of endoluminal radiofrequency ablation before stenting of malignant biliary stenoses. Methods and Materials: 54 patients with histologically proven malignant biliary stenoses have been enrolled in a prospective randomised study from 2010. 73 non-covered self-expandable metal stents were inserted. In group A (n=22) the endoluminal ablation with a bipolar radiofrequency catheter (EndoHPB;EMcision Ltd.,London,UK) was performed 0-48hours prior to the stent insertion, in group B (n=32) the stent was implanted without a prior ablation. The primary endpoints of the study were to determine the rate of complications, duration of stent patency and survival of patients (Kaplan-Meyer analysis). Results: No major complications related to the stent insertion and endoluminal ablation were recorded. 30 day mortality was 3.7%. The average primary stent patency was 5.6 and 5.2 months in group A and B, respectively, 3-months and 6-months stent failure was 9.1% and 13.6% in group A and 15% and 25% in group B. The median survival from the insertion of the stent was 5.9 (2.9-6.7) and 5.4 (3.7-8.6) months, the median survival from the initial drainage was 9.6 (5.6-12.2) and 8.5 (5.8-12.7) months in group A and B, respectively. The difference was not statistically significant. Conclusion: In the prospective randomised clinical study the effect of an endoluminal ablation on patients survival was not proven. However, in the group of patients undergoing ablation there is a tendency of a lower rate of early stent failure. In addition, the intervention was not associated with higher rates of complications.
ER  -

ANDRAŠINA, Tomáš, Jiří PÁNEK, Jan HLAVSA, Vladan BERNARD a Vlastimil VÁLEK. Endoluminal radiofrequency ablation of malignant biliary stenoses. In \textit{European Congress of Radiology 2015}. 2015. ISSN~1869-4101. Dostupné z: https://dx.doi.org/10.1007/s13244-015-0387-z.

Podrobný výpis o publikaci